|
**Overview**: PCOs Congenital Adrenal Hyperplasia Steroid Panel**Introduction**: The Polycystic Ovary Syndrome Congenital Adrenal Hyperplasia Steroid Panel is a diagnostic tool designed to differentiate PCOS and CAH using serum samples. In India, PCOS affects ~20-30 percent of reproductive-age women (higher in urban/obese), while non-classic CAH (late-onset 21-OH deficiency) mimics PCOS with hirsutism, irregular cycles, and infertility. High morbidity from misdiagnosis in rural/low-SES women with androgen excess, limited endocrine labs, delayed targeted therapy (metformin/anti-androgens vs glucocorticoids) leading to prolonged infertility or metabolic complications. Per endocrinology practices aligned with ICMR, Endocrine Society of India, and FOGSI guidelines, the test employs spectrophotometry for 17-OHP, testosterone, DHEAS, androstenedione, and cortisol over 1-2 days with high accuracy, valuable for distinguishing CAH (marked 17-OHP elevation) from PCOS (mild androgen excess). This diagnostic falls under endocrine screening and targets women with hirsutism/PCOS features, addressing accurate detection to guide appropriate therapy and prevent misdiagnosis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise differential profiling and reducing reproductive/metabolic burden. Its serum-based approach ensures reliable steroid differentiation.**Other Names**: PCOS CAH Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/endocrinology, compliant with 2025 standards.**Historical Milestone**: 17-OHP screening for CAH vs PCOS standard; in India, used in infertility clinics.**Purpose**: The test assesses 5 parameters including 17-OHP to guide PCOS/CAH differentiation, detect androgen excess patterns, inform therapy.**Test Parameters**: 1. 17-OHP, 2. Testosterone, 3. DHEAS, 4. Androstenedione, 5. Cortisol.**Pretest Condition**: Fasting 10-12 hours recommended; patients should have androgen excess symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve steroid integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on hirsutism, cycles, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of misdiagnosis including infertility, benefits of differentiation, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Markedly elevated 17-OHP indicates non-classic CAH; moderate androgens + normal 17-OHP suggests PCOS, necessitating specialist input.**Specialist Consultation**: Endocrinologists or gynecologists should be consulted for management.**Additional Supporting Tests**: ACTH stimulation, pelvic ultrasound for confirmation.**Test Limitations**: Overlap in mild cases; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, PCOS/CAH Studies India 2023. |
